Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title
13 Nov 2007 Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
13 Nov 2007 Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
12 Nov 2007 Akela Pharma Announces Final Positive Results From Its Growth Hormone Releasing Hormone (GHRH) Phase II Trial
12 Nov 2007 DIREVO and Pfizer collaborate on therapeutic proteases
09 Nov 2007 Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
09 Nov 2007 PTH 1-34, Phase 2a Clinical Trials Initiated
07 Nov 2007 Biovitrum Announces Future Roadmap - Increased Focus on Specialist Care Diseases
07 Nov 2007 BioGeneriX and Neose Technologies Announce Positive Data from Two Phase I Studies of GlycoPEG-GCSF
07 Nov 2007 Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
05 Nov 2007 Bayer Temporarily Suspends Global Trasylol(R) Marketing
05 Nov 2007 MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
05 Nov 2007 Transition Therapeutics Provides Update on Diabetes Program
05 Nov 2007 Affymax(R) Announces Hematide(TM) Successfully Restores Hemoglobin in Patients with Pure Red Cell Aplasia (PRCA)
05 Nov 2007 Human genome sciences presents results of Phase 2 trial of albuferon(R) in chronic hepatitis c patients who failed to respond to previous therapy
05 Nov 2007 Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
02 Nov 2007 Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin(R) for RDS in Premature Infants
02 Nov 2007 Protox Announces Positive Final Data From Prostate Cancer Study
01 Nov 2007 TransMolecular Reports Positive Phase 1 Trial of131Iodine Radiolabeled TM-601 in Glioma
01 Nov 2007 Manhattan Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Topical PTH (1-34) for Psoriasis
31 Oct 2007 Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
31 Oct 2007 Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
31 Oct 2007 CLIPS(TM) protein Pieris and Pepscan to identify GPCR-specific Anticalins(R) using mimicry technology
31 Oct 2007 Altea Therapeutics Announces Positive Clinical Results for its Basal Insulin Transdermal Patch in Patients with Type 1 Diabetes
31 Oct 2007 TransMolecular Reports Positive Phase 1 Trial of 131 Iodine Radiolabeled TM-601 in Glioma
30 Oct 2007 Jerini Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review
27 Oct 2007 Chemokine Therapeutics Investigator Presents Encouraging Preliminary Results From CTCE-9908 Phase I/II Clinical Trial
26 Oct 2007 Unigene Reports Successful Completion of Oral Calcitonin Human Study
25 Oct 2007 Paion reports successful start of Phase I study with anticoagulant solulin
24 Oct 2007 ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
23 Oct 2007 Phylogica to take innovative burns drug into human trials
23 Oct 2007 Novo Nordisk receives approval for Levemir(R) in Japan (22 Oct 2007)
20 Oct 2007 Pivotal Mircera study first to convert dialysis patients from frequent dosing directly to once every four weeks
19 Oct 2007 Novel agent for treatment of cerebral stroke and other diseases with neuronal damage in clinical phase I
19 Oct 2007 Paion sees continued development rationale for Desmoteplase based on findings from phase III analysis
19 Oct 2007 Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss
19 Oct 2007 Cleveland BioLabs Completes Manufacturing Process for Protectan CBLB502
19 Oct 2007 Nektar Therapeutics Issues Statement on Exubera
18 Oct 2007 SemBioSys confirms commercially viable levels of Native APO AI in safflower
18 Oct 2007 Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus(R)
18 Oct 2007 Omiganan Phase II Rosacea Study Demonstrates Promising Results
16 Oct 2007 Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
16 Oct 2007 Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
15 Oct 2007 NRP drug effective in animal models of motor neuron disease and peripheral neuropathy
13 Oct 2007 OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
13 Oct 2007 Long-Term Study Shows COPAXONE® Significantly Slows Progression of Disability and Reduces Relapse Rates in Patients with Relapsing-Remitting Multiple Sclerosis
13 Oct 2007 Cyplasin-SC(TM) shows proof of efficacy in tumor bearing animals
12 Oct 2007 Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
12 Oct 2007 CuraGen Announces Top-Line Phase II Results on Velafermin
12 Oct 2007 Two-year Phase IIIb data show that the new formulation of Rebif® offers a near three-fold improvement in injection tolerability and reduced immunogenicity
12 Oct 2007 Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 351 - 400 of 1307

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics